The CD3+CD56+ subset of cytokine-induced killer (CIK) cells, which are developed from blood and cultured with recombinant IL-2, was considered more effective against tumors due to its enhanced ability to target and destroy cancer cells. Here, NCAM1 is linked to cancer.